Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457118 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01457118: Completed Phase 2 study, sponsored by Nektar Therapeutics.
NCT01457118 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01457118, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.
Primary Outcome
To provide access to NKTR-102 to subjects who previously received NKTR-102 in a clinical trial and were without signs of disease progression since receiving NKTR-102.
Interventions
- DRUG NKTR-102 145 mg/m2
- DRUG NKTR-102 120 mg/m2
- DRUG NKTR-102 95 mg/m2
- DRUG NKTR-102 50 mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-10 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
What the finished NCT01457118 record still lists
NCT01457118 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 4 interventions - of which NKTR-102 145 mg/m2 is the first listed.
NCT01457118 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01457118 about?
NCT01457118 is a clinical study titled "An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies". The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKT...
What is the current status of trial NCT01457118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2011-10. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01457118?
The interventions under investigation include: NKTR-102 145 mg/m2 (DRUG), NKTR-102 120 mg/m2 (DRUG), NKTR-102 95 mg/m2 (DRUG), NKTR-102 50 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT01457118?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01457118's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia